Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676) | Zendy

De Vetten M. P. | Zendy; Jansen J. H. | Zendy; Van Der Reijden B. A. | Zendy; Berger M. S. | Zendy; Zijlmans J. M. J. M. | Zendy; Löwenberg B. | Zendy

Premium

Molecular remission of Philadelphia/bcr‐abl‐positive acute myeloid leukaemia after treatment with anti‐CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA‐676)

Author(s) -

De Vetten M. P.,

Jansen J. H.,

Van Der Reijden B. A.,

Berger M. S.,

Zijlmans J. M. J. M.,

Löwenberg B.

Publication year - 2000

Publication title -

british journal of haematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.907

H-Index - 186

eISSN - 1365-2141

pISSN - 0007-1048

DOI - 10.1111/j.1365-2141.2000.02402.x

Subject(s) - gemtuzumab ozogamicin , calicheamicin , cd33 , medicine , conjugate , myeloid leukemia , cd34 , stem cell , biology , mathematical analysis , genetics , mathematics

The anti‐CD33 monoclonal antibody linked to NAc‐gamma calicheamicin gemtuzumab ozogamicin (CMA‐676) was used to treat a patient with Philadelphia/bcr‐abl‐positive acute myeloid leukaemia. We report a morphological and cytogenetic complete remission after treatment with two doses of gemtuzumab ozogamicin as a single agent. Using real‐time polymerase chain reaction (PCR), gemtuzumab ozogamicin treatment resulted in a 3‐log tumour mass reduction in bone marrow.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research